EuroDURG bulletin

No. 32 January 2023

NEWSLETTER OF THE EUROPEAN CHAPTER OF THE SPECIAL INTEREST GROUP OF DRUG UTILISATION RESEARCH (SIG-DUR) OF THE INTERNATIONAL SOCIETY OF PHARMACOEPIDEMIOLOGY (ISPE)

Editors The Bulletin was prepared by the EuroDURG board members, SIGDUR chairs, chairs of regional chapters and other active DUR people. See contributors below each paragraph. Edited by Ria Benko. Send reactions to: benkoria@gmail.com

The Chair's message

Dear colleagues,

It is the start of 2023, with this Bulletin we would like to look back on the work we have done in the last year and look ahead of what is coming. A lot of our EuroDURG time in 2022 was spent on two big projects: first, the preparation of the second edition of the book, Drug Utilization Research: Methods and Applications which will be again published by Wiley. Monique Elseviers and Bjorn Wettermark are the important driving forces. There are a few steps left before we have the full draft of the updated edition. Second, the planning of the conference on Drug Utilization Research in Bologna, in June 2023 with the title: "Sustainability of drug use: equity and innovation". Elisabetta Poluzzi is the chair of the local organizing committee and Bjorn Wettermark is the chair of the scientific committee. We are looking very much forward to meeting you in Bologna. At the time of sending out the Bulleting, there are probably a few days left to submit an abstract. You can find more information on the conference in the Bulletin and here: https://eventi.unibo.it/eurodurg2023.

We also continued contributing to various European Drug Utilization research projects, like the Happy Patient project (www.happypatient.eu), the project on polypharmacy in older adults in six European countries in collaboration with IQVIA, the DURDAM project and many others. We will go on working on those projects in 2023. You can read much more about these on the next pages.

Our successful collaboration with the International Society of Pharmacoepidemiology (ISPE), especially, with the SIG DUR, with colleagues from all around the globe continued. You can also find an announcement of ISPE's next conference in this Bulletin, planned to be run in August in Halifax in Canada. We encourage you to submit abstracts, so we will have a lot of drug utilization research at the conference!

Next to the Bulletin, we keep expanding our activities using various forms of social media. You can follow us on LinkedIN (https://www.linkedin.com/company/euro-durg/) and on twitter

(https://twitter.com/eurodurg). If you are an early career researcher, you can join the LinkedIn network of DUR early career researchers. Please contact Ana Thomas or Irina Iaru (see contact details at the end) if you are interested.

How can we improve sustainable use of medicines? Which interventions enhance the quality use of medicines? How can we maximize resource use and inform health policies to improve public health? What is the best use of real world evidence to support personalized medicine and tailored treatment choices? These are just a few questions that our growing EuroDURG community work on. I like to thank all the members of the Core Committee and the EuroDURG Board members who have contributed so much time and efforts to make our activities successful. I very much appreciate their hard work and the fun we had during this year!

So, please take time to read the Bulletin to learn more about our activities. Join in where possible and contact us with questions and ideas. I hope to see many of you in Bologna in June 2023!

Katja Taxis
Chair of EuroDURG
European chapter of ISPE SIG DUR

EuroDURG's communication with DURs

As you could read in the chair's message you can find us on LinkedIn and Twitter to stay up to date with all the activities we have planned for 2023. Over the past two years, our social media pages have become an avenue to easily disseminate EuroDURG activities, including updates on projects, announcement of the new edition of the DUR book, the ENABLE training school, and of course, the upcoming EuroDURG 2023 conference in Bologna.

Our social media community is growing in numbers, and we would like to thank everyone who is following us and interacting with our updates. Since launched, our LinkedIn page has gathered more than 250 followers, and the different content has been shown over the feeds of LinkedIn members more than 10.000 times with more than 400 unique visitors to our LinkedIn page. We look forward to growing our network further, and we count on you, like-minded DUR enthusiasts, to make that happen.

Ana Tomas and Irina Iaru

SHORT SUMMARIES FROM ONGOING PROJECTS

Second edition of the DUR book



The second edition of our DURbook is in full development. All EuroDURG board members engaged to take the responsibility for leading one of the sections of the new edition. Apart from a monthly teams meeting, the editorial board assembled four times in 2022 for a full weekend of intensive 'book' working in Vilnius, Copenhagen, Uppsala and Bologna, respectively. During these weekends, all submitted chapters received a first internal review. After approval by the internal reviewers, chapters are sent out for external review. Currently most of the chapters are in this process of external review. In March, a complete first version of the book will be submitted to Wiley. We look forward to presenting you a new edition of the DURbook at the next EuroDURG conference in Bologna in June 2023.

Monique Elseviers

Guideline for Cross-National-Comparison (CNC) studies

Based on an ISPE research grant, EuroDURG board members in collaboration with Yared Santa-Ana-Tellez and Carlos Durán developed a Guideline for designing, conducting, analyzing and reporting cross-national comparison of drug utilization data. After a final editing round and definitive approval by ISPE, the guideline will be submitted to the journal of Pharmacoepidemiology and Drug Safety (PDS) for publication. In addition to the guideline, a checklist will be available that can be used by authors and reviewers to check the quality of the CNC study.

Monique Elseviers

Increasing access to Drug Utilization data: Glasgow declaration

During our 2017 conference in Glasgow, EuroDURG has taken the initiative to develop a declaration aiming to improve the availability and accessibility of drug utilization data worldwide. This *Glasgow Declaration* was further discussed during a workshop at the ISPE conference in Prague in 2018 and the EuroDURG conference in Szeged in 2020. Then, the declaration was sent to ISPE seeking for official endorsement. The Public Policy Committee of ISPE launched a call for member comments resulting in a limited number of queries and suggestions. ISPE endorsed the statement on 23 February 2022.

We are still discussing with ISPE how to place the Declaration on their website. Once posted, the declaration will be communicated to a wider audience in the field of drug utilization and pharmacoepidemiology to secure their support through a broad subscriber endorsement process. Our final intention is to bring the Glasgow Declaration to the attention of health policy makers responsible for improving the availability and access to drug utilization data.

Monique Elseviers

Happy Patient Project	

EuroDURG participates in the EU Happy Patient project aimed at researching health care professional-patient strategies to reduce inappropriate antibiotic consumption. The APO method, developed by the RUPO team in Denmark is applied in four sectors, general practice, out of hours services, nursing homes and community pharmacies across five countries, Spain, France, Poland and Greece and Lithuania. EuroDURG contributes to the work package which focuses on the adaptation of EU Guidelines for community pharmacies in the target countries. The work package is led by Katja Taxis and Maarten Lambert from University of Groningen in collaboration with Ria Benko. The 2nd year of this 3 year project is just completed. In all sectors, in all countries, the health care professionals completed standardised audit sheets to document the practice of prescribing and dispensing antibiotics. All participants were invited to an educational intervention how to improve prescribing and dispensing. This year, all participants will complete the second registration of practice. Results focusing on the community pharmacy setting will be presented at the EuroDURG meeting in Bologna. Also, first results from the pilot study in the community pharmacies have been published and can be found here: https://www.mdpi.com/2079-6382/11/11/1529

Much more information is also available on the Happy Patient website: www.happypatient.eu

Alongside the Happy Patient project, we are currently conducting a study to develop a guideline on appropriate dispensing of antibiotics in community pharmacy. If you are interested in research on the development and evaluation of the role of the community pharmacist to improve antibiotic use and reduce antimicrobial resistance, please get in touch.

Katja Taxis

Drug Utilization Research Database Appraisal of Maturity (DURDAM)	

This is a consensus development study using Delphi methods to identify "what is maturity of DU databases". This consensus will be used to create a national DU databases maturity appraisal tool. The usability and acceptability of the tool will also be assessed. The protocol is available here OSF | Drug utilization Research Databases Appraisal of Maturity (DURDAM): Protocol for an International Modified Consensus Study. The reqruitment starts in Febuary, primary results will be presented at EuroDurg conference in Bologna this June.

Drug utilization Research Databases Appraisal of Maturity (DURDAM): Protocol for an International Modified Consensus Study

Contributors: Sean MacBride-Stewart, Indre Treciokiene, Hege Salvesen Blix, Gisbert W. Selke, Lisa Pont, Atėnė Marija Theofylaktou, Katja Taxis, Bjorn Wettermark, Monique Elseviers

Date created: 2022-11-15 09:45 AM | Last Updated: 2022-12-21 03:06 PM

Identifier: DOI 10.17605/OSF.IO/CVWZ9

Category: Project

Description: *This is a two phase project. First a Modified Delphi consensus process of three rounds will be used to build a databases assessment tool. In the second phase the accessibility and usability of this National DU Databases Appraisal Tool will be tested using questionnaires.*

Indre Treciokiene, Sean MacBrideStewart

IQVIA project	IQVIA

The prevalence of polypharmacy and the use of potentially inappropriate medications – a cross-national study in 6 European countries

EuroDURG (lead by Marion Bennie and Katja Taxis) has been working collaboratively with IQVIA to undertake a multi-country study, using IQVIA databases, to explore the prevalence of polypharmacy in the elderly population (age above 65 years) and examine the use of selected PIMS (potentially Inappropriate Medication): opioids; antipsychotics; benzodiazepines, and proton pump inhibitors. The study spans six countries : Belgium, France, Germany, Italy, Spain and the UK and has adopted a standardised methodology to examine the databases (generated from primary care general practice activity) with country level validation and interpretation supported by EuroDURG identified leads for five country: Belgium (Monique Elseviers); France (Lucas Morin); Germany (Ingrid Schubert); Italy (Elisabetta Poluzzi); UK(Sean Macbride-Stewart). The analysis has been undertaken by a joint IQVIA/ EuroDURG team and includes interpretation of any variations identified in context of country health care systems potentially impacting the findings. A manuscript for publication has been submitted in summer 2022.

Marion Bennie

Other European projects/surveillance/initiatives	

The CDRx project

The CDRx project is a Health Research Board funded project in Ireland, aims to understand policies and practices for safe use of analgesic and sedative medications, with a focus on controlled drugs. Time trends in volumes, the impact of policy changes and patterns of prescribing in Ireland will help to optimise regulation and use of these controlled drug medications in order to maximise benefits for patients and society. You can check https://cdrx-project.eu/ for more information about this ongoing project.

The iSIMPATHY project

iSIMPATHY (implementing Stimulating Innovation in the Management of Polypharmacy and Adherence Through the Years) project will run until March 2023. The EU funded partnership between the three jurisdictions of Northern Ireland, Scotland and the border areas of the Republic of Ireland helps enable patients taking multiple medicines to lead healthy and active lives by delivering person-centred, pharmacist-led medication reviews across primary and secondary care. The next iSIMPATHY training session for Healthcare Professionals took placeon the evening of Wednesday 11th January 2023. For more information, you can check https://www.isimpathy.eu/

The PROTECT study

This study is conducted by the Trinity College Dublin team in partnership with the James Lind Alliance, aims to identify a list of Top 10 priorities for future research on reducing and stopping psychiatric medicines from key stakeholders (people with lived experience of taking and/or stopping psychiatric medicines, family members, carers/supporters and healthcare professionals). The psychiatric medicines of direct interest to this study are antidepressants, anxiolytics, antipsychotics, hypnotics, and mood stabilisers. More information about the project and how to get involved can be found here: https://tapersafer.org/the-protect-study/about-the-study .

The international DEPRESCRIBING JOURNAL CLUB

The first international deprescribing journal club was launched on Oct 5th, 2022. There are quarterly sessions held by the Canadian Medication Appropriateness and Deprescribing Network in collaboration with international partners. Clinicians and researchers around the globe gather to connect and discuss recent deprescribing publications and complex clinical cases. The next meeting will be hosted by the Australian Deprescribing Network on March 29th, 2023. You can check https://www.deprescribingnetwork.ca/journal-club for updates.

Irina Iaru

A pan-European project on medication adherence	

The EU-funded European Network to Advance Best practices & technoLogy on medication adherencE (ENABLE) project started in 2020 with the aims to:

- raise awareness of adherence enhancing technological solutions,
- foster and extend multidisciplinary knowledge on medication adherence at patient, treatment and system levels,
- accelerate translation of this knowledge to useful clinical application and
- work collaboratively towards economically viable implementation of adherence enhancing technology across European healthcare systems.

The network include more than 100 researchers from 40 European countries. During 2022, a conference and training school was held in Malaga, Spain focusing on patient engagement. Surveys were conducted to policymakers and healthcare professionals and a number of researchers were funded for scientific visits to other universities to learn and establish research collaboration around adherence. Finally, terminologies around digital tools have been refined and a database will soon be released where it is possible to search for available digital solutions to improve medication adherence. During 2023, steps will be taken to stimulate the establishment of national centers of excellence for adherence in different countries. There will also be a training school on digital tools in medication adherence, in connection with the EuroDurg conference in Bologna in June 2023.

Drug utilization researchers interested in medication adherence are most welcome to join the Enable project. More information is found on the project website https://enableadherence.eu/

Björn Wettermark

ISPE SIG-DUR NEWS

The SIG DUR invites everyone to attend an online symposium on 27 March 2023, 12-2 PM CET. The agenda of the symposium will include SIG DUR updates and presentations of exciting DUR from our members. As a new initiative, there will also be a chance to split into smaller subgroups with special interest in specific topics. If you want to present work or update folks, email Lotte Rasmussen (lorasmussen@health.sdu.dk) before 1 March 2023. Please invite other colleagues- an E-vite will be available on the ISPE community site. The more the merrier is our motto so please feel free to include others who are interested.

Mina Tadrous

Insight into ENCePP activities

The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP®) is a network coordinated by the European Medicines Agency (EMA). The members of this network (the ENCePP partners) are public institutions and contract and research organisations involved in research in pharmacoepidemiology and pharmacovigilance. Research interests are not restricted to the safety of medicines but may for example include drug utilization research and ISPE has a member on the board of ENCePP. The ENCePP website (http://www.encepp.eu) describes the activities of the network and provides access to documents and information on the ENCePP partners.

Among highlights of 2022 activities, a list of metadata describing real-world data sources and studies hasbeen published by the EMA, to help pharmaceutical companies and researchers to identify and use real world data when investigating the use, safety and effectiveness of medicines. Following extensive consultation with stakeholders, including ENCePP partnerss, the chosen metadata will be included in a catalogue of data sources containing information about existing real-world databases (to replace the current ENCePP catalogue) and information about the studies performed on the data sources (to replace and enhance the current EU PAS Register). A number of studies with a drug utilization focus are entering into this EU PAS Register. Setting up a catalogue of data sources and enhancing the catalogue of studies aims to improve transparency with regard to observational studies, enhanced discoverability of studies and

data sources, and contribute to increasing the ability to judge the evidentiary value of studies when used to investigate the use, safety and effectiveness of medicinal products.
ENCePP held its virtual annual plenary meeting for its partners on 30 November 2022. The meeting had a number of interesting sessions where one session highlighted how evidence from independent pharmacoepidemiological vaccine studies has contributed to EMA decision making in public health crisis management for COVID-19. ENCePP can contribute to this effort by fostering good practices, methods, and selection of suitable data sources.

Anna Birna Almarsdottir

Insight into EMA activities

In February 2022 EMA established the Coordination Centre for the Data Analysis and Real World Interrogation Network (DARWIN EU®). The role of the Coordination Centre is to develop and manage a network of real-world healthcare data sources across the EU and to conduct scientific studies requested by medicines regulators and, at a later stage, requested by other stakeholders. The vision of DARWIN EU® is to give EMA and national competent authorities in EU Member States access to valid and trustworthy real-world evidence, for example on diseases, patient populations, and the use, safety and effectiveness of medicines, including vaccines, throughout the lifecycle of a medicinal product. By supporting decision-making on the development, authorisation and surveillance of medicines, a wide range of stakeholders will benefit, from patients and healthcare professionals to health technology assessment bodies and the pharmaceutical industry. Additionally, DARWIN EU® will provide an invaluable resource to prepare for and respond to future healthcare crises and pandemics.

Coordination Centre will set up the necessary infrastructure and establish the required business services to run scientific studies to answer research questions that come up during the evaluation of medicines in the EU and also maintain a catalogue of real-world data sources and metadata for use in medicine regulatory activities. All studies will be published in the EU catalogue of observational studies. The first DARWIN EU® pilot studies will be delivered in 2022.

Katarina Gvozdanović

News from other regions/continents	

	*Africa*

In 2022 the ISPE AfRIG leadership consisted of Dr Kwame Appenteng who is the chair of ISPE Africa who is supported by Prof Irene Berita Murimi as vice-chair. The regional leaders are:

Central Africa	
Didier Nzol	University of Kinshasa, Democratic Republic of the Congo
Akindeh Nji	University of Yaounde I, Cameroon
Eastern Africa	
Dan Kajungu	Makerere University, Uganda
Sylvia A Opanga	University of Nairobi, Kenya
Western Africa	
Daniel Ankrah	Korle-bu Teaching Hospital, Ghana
Chioma Ejekam	Lagos University Teaching Hospital, Nigeria
Southern Africa	
Ilse Truter	Nelson Mandela University, South Africa
Karen Cohen	University of Cape Town, South Africa
Johanita Burger	North-West University, South Africa

2nd ISPE AfRIG Conference

The second ISPE AfRIG Conference took place from 11 to 13 July 2022 (virtually). The conference theme was "Optimising real world data use for healthcare research and policy in Africa – Data sourcing and capabilities development".

The abstract book is available at: https://virtual.oxfordabstracts.com/#/event/2965/information

Judith K Jones Award

The year 2022 was the inaugural year for this award which was created in honour of Judith K Jones, a key ISPE leader, who inspired many of us with her contributions to ISPE. The Judith K Jones Award recognises individuals making a demonstratable impact on public health through work in the area of pharmacoepidemiology.
Prof Ilse Truter from South Africa and Prof Luciane Lopes from Brazil were in 2022 the co-recipients of the inaugural Judith K Jones Award for Impact on Public Health through Pharmacoepidemiology.

Plans for the coming year

The 3rd ISPE AfRIG 2023 Conference will be hosted at the V&A Waterfront in Cape Town from 5th to 9th June 2023. The first two days will consist of a selection of educational training courses, followed by a 3-day conference. The local host committee is Prof Karen Cohen (University of Cape Town), Prof Johanita Burger (North-West University) and Prof Ilse Truter (Nelson Mandela University).
For more information, you are welcome to contact me at: ilse.truter@mandela.ac.za

Ilse Truter

Latin America

ISPE BRAZInt RIG and ISPE LATAM RIG

BrazInt RIG's incentive has continuously been the development of joint research manuscripts, as we feel this is the booster to bring more members and develop pharmacoepidemiology and DUR in our region/countries. We already published four manuscrits (Cañás et al PMID: 34105332; Leal et al. PMID: 35115935; Lopes et al PMID: 34957616; Rodríguez-Tanta et al. 10.3389/fphar.2022.1047946) and there are three more in preparation to be submitted to the journal. BRAZInt RIG has good interaction with others ISPE RIGs/SIG – Africa RIG, SIG DUR, SIG Biologics and SIG Deprescribing. Chair and Co-Chair of BRAZInt RIG are part of the Scientific committee of the EuroDURG Meeting in Bologna.

We kept once-a-month webinars with topics suggested by members, considering methodological aspects of pharmacoepidemiology and important topics for the region. Up to August 2022 we presented four webinars and two important symposiums: 1) Symposium satellite VI Rational Use of Medicine and Seminar of RADAR project – Sex differences and adverse events of antiretroviral in people living with HIV/AIDS - https://www.uniso.br/evento/vi-rum e; 2) Drug Utilisation Research Using Secondary Databases Online Seminar July 5-7, 2022https://www.onlineseminar.com.br/ (see details below).

During the 38th ICPE 2022 in Copenhagen, Denmark, a strategy to strengthen the region and reduce duplication of effort, ISPE's Global Development Committee (GDC) proposed the merger of RIG LARIG and BRAZint. BRAZint composed of a majority of Brazilian researchers and 30% of Latin American, European and North American researchers and LARIG formed by researchers essentially from South America. By common agreement, LATAM RIG was formed, composed mainly of Latin American researchers and those who wish to work on research projects involving the region. The chair of LATAM RIG is Luciane Cruz Lopes, co-chair is Yesenia Rodriguez while liaison person is Maribel Salas in GDC.

The new strategy adopted by LATAM RIG was to create a board with representatives from each Latin American country that disseminates and involves researchers from their respective countries. Actions are proposed and discussed by this board, which are passed on to other researchers in each country. The board includes representatives from Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Mexico, Peru and Uruguay. Each board member has the task of creating a chapter for students from each country to form a Latin American group for training researchers in pharmacoepidemiology. Soon we will propose activities for students to participate in pharmacoepidemiology congresses, educational workshops and expand their network to establish collaborations for master's and doctoral courses.

BRAZILIAN STUDENT CHAPTER ISPE

The Brazilian student group's objective is to promote interest in Pharmacoepidemiology, engaging new researchers and increasing the quality of research and discussions carried out in Brazil. The first Brazilian chapter was created in 2019 (ISPE-UFRGS), and since then, the group has worked to be recognized as a national network of pharmacoepidemiology. Several movements were made to amplify the actions, including recurrent meetings and the creation of a second chapter (ISPE-UNISO). Together we have organized the "Ist Symposium of ISPE Brazilian Student Chapters" within the "Vth International Workshop on Rational Use of Medicines", having as a keynote speaker Dr. Sami Suissa. At the same event, we held the first meeting with UNISO and UFRGS chapters to present the ISPE student chapters in Brazil.

In 2021, both chapters were merged to create the ISPE Brazilian Student Chapter: "Grupo Brasileiro de Estudantes da Sociedade Internacional de Farmacoepidemiologia – GBE/ISPE", an attempt to harmonize and centralize the activities. In 2022, recurrent bi-weekly board meetings were established, and the open letter presenting the GBE/ISPE was distributed among representatives of six Brazilian Universities who were committed to connecting the ISPE Brazil Board and the students. Journal Clubs in Portuguese and a mentorship program for helping Brazilian students to publicize their research are planned to start this year.

Currently, the GBE-ISPE count with 61 participants with whom we have shared national and international opportunities concerning pharmacoepidemiology training. The GBE-ISPE will work in 2023 to consolidate the Brazilian group and then inspire other Latin American students, working together with the ISPE-LATAM

Luciane Cruz Lopes (Chair)

Drug Utilization Research Using Secondary Databases International Online Seminar Jul 5-7, 2022	

Since 2013 our research group on Essential Medicines and Pharmaceutical Services has organized international seminars on Drug Utilization Research and Pharmacoepidemiology at the Sergio Arouca National School of Public Health in Fiocruz, Rio de Janeiro, Brazil, namely: the International Seminars "Pharmacoepidemiology Research in Latin America" (April, 2013), "Pharmacoepidemiology Research on Essential Medicines" (November, 2015), "Drug Utilization Research in Country and Health System Contexts" (September 2017) and the Short Course "Methods in Pharmacoepidemiology: Applications for DUR" (November 2019).

Earlier seminars counted with participation of ISPE representatives and a number of researchers from Chile, Colombia, Mexico, Peru, Sweden, England, Hungary, Belgium, Australia, Scotland, Guatemala, Scotland. This was the fifth event in the series. Our aim is to network with various international experts, join South and Central American researchers, present and discuss work in DUR and pharmacoepidemiology and involve graduate students and health managers.

The 2022 seminar "Drug Utilization Research Using Secondary databases" was financed by FAPERJ and counted with lectures and round tables joining international invitees Bjorn Wettermark (Sweden), Ria Benko (Hungary), Indrė Trečiokienė (Lithuania), Angela Acosta (Colombia), Carlos Duran (Netherlands/Ecuador), Petra Sevcikova (Germany/Slovakia) and Brazilian researchers: Claudia Osorio-de-Castro, Org (Fiocruz), Rosângela Caetano, Org (UERJ), Elisangela Lima, Org (UFRJ), Elaine Miranda, Org (UFF) and Mario Sobreira, Org (INCA); Claudia Medina (UFRJ), Luciane Lopes (UNISO) and Augusto Guerra (UFMG). The seminar was attended by around 350 participants, who registered online.
https://www.onlineseminar.com.br/

Claudia Osorio-de-Castro (chair of the event)

Canada	*Canada*

The Canadian Network for Observational Drug Effect Studies which examines drug utilization, safety and effectiveness post marketing, which was established in 2011, was refunded (www.cnodes.ca).

In Canada, no national network for DUR exist, health care is delivered by provinces and the DUR researchers work in each province. Nova Scotia is one of them and the DUR community there published three interesting papers last year. One examines patterns of antipsychotic dispensations to long term care residents (PMID: 36309099) and two studies examine community pharmacist prescribing (PMID: 36038458, PMID: 36703714).

Canadian drug utilization researchers are assisting with the organization of the ICPE meeting in Halifax, Nova Scotia Canada in August 2023

Ingrid Sketris

FUTURE PLANS & EVENTS

Upcoming conferences…	

Below we list all forthcoming English language international conferences that may interest DUR people. The list is not inclusive, further meeting of regional ISPE chapters can be fond on ISPE webpage.

EuroDURG	 June 27-30, 2023 Bologna, Italy

International Society of Pharmacoepidemiology (ISPE)

ISPE 2023 Mid-year meeting: https://www.eventscribe.net/2023/ISPEMY2023/

ISPE 2023 Annual conference: https://www.pharmacoepi.org/meetings/annual-conference/

Abstract submission: https://myemail.constantcontact.com/2023-ICPE-Call-for-Abstracts-Now-Open-DEADLINE-FEB-13.html?soid=1102594618795&aid=mpgfQSGqbyY

ispe International Society for Pharmacoepidemiology	 Abstract submission deadline: th **13 February, 2023**

International Society of Pharmacovigilance (https://isoponline.org/) https://isoponline.org/annual-meetings/isop-2023-annual-meeting/	

European Association for Clinical Pharmacology and Therapeutics (https://eacpt.org) https://www.eacpt2023.org	

European Society of Clinical Pharmacy (https://www.escpweb.org/) ESCP Spring Workshop 2023: https://escpweb.org/escp_events/escp-spring-workshop-2023/ ESCP Symposium 2023 in Aberdeen: https://escpweb.org/workshops-and-symposia/upcoming-events/	

Health Technology Assessment International (https://htai.org/) https://htai.org/annual-meetings/	

European Society for Patient Adherence, Compliance, and Persistence (https://www.espacomp.eu/); https://www.espacomp.eu/annual-meetings/	

Nordic Pharmacoepidemiologic Network (www.norpen.org) http://www.norpen.org/pages/meetings.html	

Gabriel Sanfélix-Gimeno

Contact addresses of board members

Katja Taxis (chair)
Groningen Research Institute of Pharmacy (GRIP)
Unit PharmacoTherapy, -Epidemiology & -Economics
University of Groningen
Ant. Deusinglaan 1
9713 AV Groningen
THE NETHERLANDS
Tel: +31- (0)50 - 363 8205
Email: k.taxis@rug.nl

Marion Bennie (past chair)
Strathclyde Institute of Pharmacy and Biomedical Sciences
University of Strathclyde,
Room 501a Robertson Wing
Taylor Street
Glasgow, G4 0NR
SCOTLAND
Tel: +44 (0) 141 548 2113
Email: marion.bennie@strath.ac.uk

Björn Wettermark (past chair)
Department of Pharmacy
Disciplinary Domain of *Medicine* and *Pharmacy*
Uppsala university
Visiting adress: Biomedicinskt Centrum BMC, Husargatan 3, 752 37 Uppsala
Postal adress: Box 580, 751 23 Uppsala
SWEDEN
Phone: +46 70 558 56 41
E-mail: bjorn.wettermark@farmaci.uu.se

Monique Elseviers (past chair)
University of Antwerp
Campus drie Eiken
Universiteitsplein 1
B-2610 Wilrijk
BELGIUM
Tel: +32 473 98 56 14
Email: monique.elseviers@ua.ac.be

Elisabetta Poluzzi (webmaster)
Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna
Via Irnerio, 48; 40126 Bologna
ITALY
Tel: +39 0512091809
Email:elisabetta.poluzzi@unibo.it

Ana Tomas Petrović (Linkedln manager)
Department of Pharmacology, toxicology and clinical pharmacology,University of Novi Sad
Hajduk Veljkova 3, 21000 Novi Sad,
SERBIA
Tel: +381606798476
E-mail: aanaa_tomas@yahoo.com

Irina Iaru (Cazacu) (Linkedln manager)
Department of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy
University of Medicine and Pharmacy "Iuliu Hatieganu",
6A Louis Pasteur Street, 1st floor, 400012 Cluj-Napoca
ROMANIA
Tel: +40746229455
Email: Cazacu.Irina@umfcluj.ro

Anna Birna Almarsdóttir
Department of Pharmacy (Social and Clinical Pharmacy)
University of Copenhagen,
Universitetsparken 2, 2100 Copenhagen
DENMARK
TEL +45 35333715
Email: aba@sund.ku.dk

Gabriel Sanfélix-Gimeno
Health Services Research Unit
Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)
Av. Catalunya 21, 46020 Valencia
SPAIN
Tel:+34 961925916
Email: sanfelix_gab@gva.es

Indrė Trečiokienė
Pharmacy center, Institute of Biomedical Science
Faculty of Medicine, Vilnius University,
M. K. Ciurlionio str. 21/27, LT-03101 Vilnius,
LITHUANIA
Tel: +37052398771,
E-mail: indre.treciokiene@mf.vu.lt

Gisbert W. Selke
AOK Research Institute (WIdO)]
Rosenthaler Str. 31, 10178 Berlin
GERMANY
Tel:+49-3034646-2393
Email: gisbert.selke@wido.bv.aok.de

Hege Salvesen Blix
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health &
The research group for personalized pharmacotherapy and clinical pharmacy
Department of Pharmacy, University of Oslo
P.O.Box 222 Skøyen, 0213 Oslo,
NORWAY
Tel: +47 21078163
Email: hege.salvesen.blix@fhi.no

Katarina Gvozdanović
School of Medicine, University of Zagreb, Zagreb, 10 000
Agency for medicinal products and medical devices
Ksaverska cesta 4
Zagreb 10 000
CROATIA
Tel:+385 (0) 99 6651 941
Email: katarina.gvozdanovic@gmail.com

Lucas Morin
Clinical Investigation Unit, University Hospital of Besançon, 2 place St Jacques, 25000 Besançon
FRANCE
Tel: + 33 (0)3 81 21 86 35
Email: lucas.morin@inserm.fr

Paraskevi (Voula) Papaioannidou
Aristotle University of Thessaloniki;
Faculty of Medicine Department of Pharmacology
University Campus
54124 Thessaloniki
GREECE
Tel:+302310 999314
Email: ppap@auth.gr

Sean MacBride Stewart
NHS Greater Glasgow and Clyde Pharmacy Services
Clarkston Court, 56 Busby Rd, Glasgow G3 8SJ
SCOTLAND
Tel: +44 141 201 6064
Mobile: +44 0790 368 0954
Email: sean.macbride-stewart@ggc.scot.nhs.uk

Sabine Vogler
WHO CC for Pharmaceutical Pricing and Reimbursement Policies Pharmacoeconomics
Department Gesundheit Österreich GmbH,
Stubenring 6, 1010 Vienna
AUSTRIA
Tel: +43 1 515 61-147
Email: sabine.vogler@goeg.at

Verica Ivanovska
Faculty of Medical Sciences
University "Goce Delcev"
Krste Misirkov 10-A, Stip 2000
NORTH MACEDONIA
Tel: +38970980671
AMR Division
World Health Organization
Avenue Appia 20
CH-1211 Geneve 27
SWITZERLAND
Tel: +41227914618
Email: vericaivanovska@hotmail.com

Ria Benkő (secretary)
Institute of Clinical Pharmacy
University of Szeged,
Szikra utca 8, Szeged H-6725
HUNGARY
Tel: +36 62 342572
E-mail: benkoria@gmail.com

For updates please visit our website:www.pharmacoepi.org/eurodurg

Please distribute this Bulletin to your colleagues!